Yes, frequent premature ventricular contractions (PVCs) can cause a form of heart failure known as PVC-induced cardiomyopathy. This happens when a high volume of extra heartbeats, typically more than 10% to 15% of all beats over 24 hours, gradually weakens the heart muscle and reduces its pumping ability. The good news: this type of heart failure is largely reversible once the PVCs are brought under control.
How PVCs Weaken the Heart
A single PVC is a premature squeeze of the heart’s lower chambers. It’s poorly timed and mechanically inefficient, meaning the heart ejects less blood with that beat. When PVCs happen thousands of times a day for weeks or months, they create a pattern of uncoordinated contraction called ventricular dyssynchrony. Instead of contracting as a unified pump, different parts of the heart muscle activate out of sync, similar to what happens with certain electrical conduction problems.
Over time, this dyssynchrony triggers a chain of changes. The heart chambers enlarge, the walls stretch, and the ejection fraction (the percentage of blood pumped out with each beat) drops. Animal studies show that persistent PVCs also cause scarring (fibrosis) in the heart muscle, disrupt the heart’s electrical signaling, and throw off the autonomic nervous system that regulates heart rate. In one animal model, 12 weeks of constant PVCs in a structurally normal heart produced measurable heart failure that took about 4 weeks to recover after the PVCs stopped. Notably, some of the scarring and electrical changes persisted even after heart function improved, which raises questions about whether the damage is truly 100% reversible in every case.
The PVC Burden That Matters
Not everyone with PVCs is at risk. The critical factor is PVC burden: the percentage of total heartbeats in a day that are premature. Research has identified several thresholds worth knowing:
- 10% or more: Associated with gradual declines in heart function and enlarged heart chambers. PVCs originating from the right side of the heart may cause trouble at this lower threshold.
- 16% or more: In one study, this predicted cardiomyopathy with 100% sensitivity and 87% specificity.
- 24% or more: Identified as a predictor of impaired ejection fraction with roughly 79% sensitivity and 78% specificity.
Some clinicians use a rough benchmark of 10,000 to 20,000 PVCs per day (out of roughly 100,000 total heartbeats) as a “high burden.” But the percentage matters more than the raw count, because total heart rate varies from person to person. PVCs that originate from the left ventricle appear to require a higher burden (around 20%) before causing problems compared to those from the right ventricle (around 10%).
Wider PVC beats also carry more risk. When the extra beat produces a QRS complex wider than 140 milliseconds on an ECG, it’s associated with lower ejection fractions, likely because wider beats create more dyssynchrony.
Symptoms to Watch For
PVCs themselves often feel like a skipped beat, a flutter, or an unusually strong thump in the chest. Many people also experience lightheadedness and fatigue. These direct symptoms can be annoying but don’t necessarily signal heart damage.
The warning signs that PVCs may be affecting your heart function are more subtle and develop gradually. Increasing shortness of breath, especially with exertion you previously handled without trouble, is one of the earliest signals. Unusual fatigue that doesn’t match your activity level, swelling in your ankles or legs, and a general decline in exercise tolerance all point toward the heart struggling to keep up. These are symptoms of heart failure developing as a consequence of the PVCs, not symptoms of the PVCs themselves.
How It’s Diagnosed
Diagnosing PVC-induced cardiomyopathy requires two things: confirming a high PVC burden and demonstrating that the heart’s pumping function has declined without another obvious cause.
PVC burden is measured with ambulatory heart monitors. A standard 24-hour Holter monitor is commonly used, but accuracy improves significantly with longer monitoring. A 2024 study found that the average error in estimating PVC burden dropped from 2.9% at 24 hours to 1.3% at 7 days and 0.7% at 10 days. Since the difference between a 10% and 13% burden could change your treatment plan, a week-long monitor gives a much clearer picture.
An echocardiogram (heart ultrasound) checks for the characteristic pattern: the heart chambers are enlarged, the overall pumping strength is reduced globally rather than in one specific region, and the mitral valve may be leaking. This global pattern helps distinguish PVC cardiomyopathy from a heart attack, which damages a specific territory. Cardiac MRI with contrast can look for scarring and rule out other conditions like infiltrative diseases or arrhythmogenic right ventricular cardiomyopathy.
Treatment: Ablation vs. Medication
The primary goal is reducing PVC burden enough for the heart to recover. Two main approaches exist, and they aren’t equally effective.
Catheter ablation, a procedure where a cardiologist threads a catheter to the heart and destroys the tissue generating the extra beats, is the more effective option. In a study comparing the two approaches in over 500 patients, ablation reduced PVC counts by about 21,800 beats per day compared to roughly 8,400 with medication. More importantly, ablation improved ejection fraction significantly (from 53% to 56% on average), while medication produced no measurable improvement. Among patients who had reduced heart function, 47% in the ablation group saw their ejection fraction normalize, compared to just 21% on medication.
Medications like beta-blockers and calcium channel blockers are typically tried first because they’re less invasive. They can reduce symptoms and modestly lower PVC counts, but they often fail to suppress the burden enough to let the heart recover. Stronger antiarrhythmic drugs carry their own risks, including potentially worsening other heart rhythm problems.
Current guidelines from the American College of Cardiology recommend pursuing PVC suppression in patients who already have cardiomyopathy and a PVC burden above 15%. For people with frequent PVCs (10% or higher) but normal heart function, the recommendation is regular monitoring with echocardiograms every 6 to 12 months to catch any decline early.
How Much the Heart Can Recover
The encouraging reality is that PVC-induced cardiomyopathy carries a better prognosis than most other forms of heart failure. In a multicenter study of patients who underwent successful ablation, the average ejection fraction improved from about 34% (well into heart failure territory) to nearly 46% at 12 months. The percentage of patients in the mildest symptom category jumped from 23% before the procedure to 79% a year later.
Long-term data from a secondary analysis of the CHF-STAT study found that patients with PVC-induced cardiomyopathy had significantly better survival and fewer cardiac events over five years compared to patients with heart failure from other causes. Once PVC suppression was achieved, it tended to hold: about 82% of patients maintained the same level of suppression between 6 and 12 months, and 77% maintained it between 6 and 24 months.
There is a caveat. Animal research shows that even after heart function bounces back, some degree of fibrosis, electrical remodeling, and dyssynchrony during normal beats can persist. This raises the possibility that people who’ve had PVC cardiomyopathy may remain vulnerable if the PVCs return or if another cardiac stress develops. The American Heart Association formally recognized PVC-induced cardiomyopathy as a distinct condition in 2016, and understanding of its long-term implications is still evolving.
Who Is Most at Risk
Several factors beyond raw PVC burden influence whether someone develops cardiomyopathy. PVCs originating from certain locations, particularly the right ventricular outflow tract or epicardial sites, tend to produce wider, more dyssynchronous beats. People whose PVCs have variable timing (the interval between the normal beat and the extra beat keeps changing) appear to experience more disruption to the heart’s nervous system regulation than those with a fixed, predictable pattern.
Duration of exposure matters too. Someone who has had a 15% PVC burden for years is at greater risk than someone whose burden spiked temporarily during a stressful period. And there’s significant individual variation: some people tolerate high PVC burdens for years without measurable heart damage, while others develop dysfunction at relatively modest levels. This unpredictability is exactly why routine monitoring is recommended for anyone with a burden above 10%, even if the heart looks fine today.